Novo Nordisk's shares have dropped even after partnering with Hims & Hers Health to distribute its semaglutide drugs, including FDA-approved Ozempic and Wegovy, through a telehealth platform. This deal expands patient access to multiple dosages and supports strong prescription growth, especially for the Wegovy pill. Despite these positives, the stock trades at a low valuation of 11 times projected 2026 earnings and offers a 5% dividend yield, indicating the market expects challenges ahead. Investors may see potential value given the current pricing and growth prospects in oral GLP-1 sales.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
